文献速递产科母胎医学

孕期阿片类药物处方与产后新发持续阿片使用:全国性分析

New persistent opioid use after acute opioid prescribing in pregnancy: a nationwide analysis.
PubMed 文献 · Am J Obstet Gynecol · 2020-03-23

这项全国性回顾性队列研究纳入2008至2016年158425例分娩,评估孕期阿片处方与产后一年新发持续阿片使用的关联。孕期6.0%患者曾配阿片处方,其中4%出现新发持续使用;孕期阿片处方与产后新发持续使用独立相关(aOR 3.45,95%CI 3.04-3.92)。

要点

  • 孕期阿片处方者产后新发持续阿片使用风险显著升高(aOR 3.45)。
  • 围产期阿片处方亦与持续使用相关(aOR 2.28)。
  • 孕期非分娩操作增加阿片处方机会但降低持续使用风险(aOR 0.72)。

核心结论

  • 孕期接受阿片处方者产后一年内新发持续阿片使用风险更高。
  • 产科照护者需在孕期疼痛管理与阿片潜在风险间权衡。

研究设计与样本

  • 全国性回顾性队列研究,使用Optum去标识化Clinformatics Data Mart数据库。
  • 纳入2008至2016年阴道分娩或剖宫产、年龄12-55岁、产前2年至出院后1年连续参保者。
  • 仅纳入孕期阿片初治(分娩前2年至9个月未配阿片)且出院后一年内未接受操作的患者。
  • 暴露为孕期配阿片处方,主要结局为新发持续阿片使用。
  • 共识别158425例分娩,其中阴道分娩101013例(63.8%),剖宫产57412例(36.2%)。

主要发现

  • 全队列中6.0%(9429例)在孕期配过阿片处方。
  • 孕期配阿片处方的相关因素包括孕期非分娩操作(aOR 9.60,95%CI 8.81-10.47)和孕期急诊就诊(aOR 2.48,95%CI 2.37-2.59)。
  • 孕期接受阿片处方的女性中4%(379例)出现新发持续阿片使用。
  • 新发持续阿片使用的最强相关因素为孕期阿片处方(aOR 3.45,95%CI 3.04-3.92)和围产期阿片处方(出院前1周至出院后3天)(aOR 2.28,95%CI 2.02-2.57)。
  • 孕期接受操作与阿片处方增加相关,但与新发持续阿片使用降低相关(aOR 0.72,95%CI 0.52-0.99)。

临床怎么用

  • 对孕期需阿片处方的患者,应评估产后持续阿片使用风险并加强随访。
  • 围产期阿片处方也应纳入持续使用风险的考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between opioid prescribing during pregnancy and new persistent opioid use in the year following delivery. MATERIALS AND METHODS: This nationwide retrospective cohort study included patients aged 12-55 years in Optum's deidentified Clinformatics Data Mart Database who were undergoing vaginal delivery or cesarean delivery from 2008 to 2016, with continuous enrollment from 2 years before birth to 1 year postdischarge. Women were included if they were opioid naive in pregnancy (ie, did not fill an opioid prescription 2 years to 9 months before delivery) and did not undergo a procedure within the year after discharge. The exposure was filling an opioid prescription in pregnancy. The primary outcome was new persistent opioid use, defined as a pharmacy claim for ≥1 opioid prescription between 4 and 90 days postdischarge and ≥1 prescription between 91 and 365 days postdischarge. Clinical and demographic covariates were included. Analyses included descriptive statistics and multivariable logistic regression, adjusting for clinical and demographic covariates. RESULTS: Of 158,425 childbirths identified, 101,013 (63.8%) were by vaginal delivery and 57,412 (36.2%) cesarean delivery. Among all patients, 6.0% (9429) filled an opioid prescription during pregnancy. The factors associated with filling an opioid in pregnancy were having a nondelivery procedure in pregnancy (adjusted odds ratio, 9.60; 95% confidence interval, 8.81-10.47) and having an emergency room visit during pregnancy (adjusted odds ratio, 2.48; 95% confidence interval, 2.37-2.59). Of women who received an opioid in pregnancy, 4% (379) developed new persistent opioid use. The factors most associated with new persistent opioid use were receiving an opioid prescription during pregnancy (adjusted odds ratio, 3.45; 95% confidence interval, 3.04-3.92) and filling a peripartum opioid prescription (1 week prior to 3 days postdischarge) adjusted odds ratio, 2.28, 95% confidence interval (2.02-2.57). Though having a procedure during pregnancy was associated with increased receipt of an opioid prescription, it was also associated with reduced new persistent opioid use (adjusted odds ratio, 0.72; 95% confidence interval, 0.52-0.99). CONCLUSION: Women who receive an opioid prescription during pregnancy are more likely to experience new persistent opioid use. Maternity care providers must balance pain management in pregnancy with potential risks of opioids.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Peahl AF, Morgan DM, Dalton VK, et al. New persistent opioid use after acute opioid prescribing in pregnancy: a nationwide analysis. Am J Obstet Gynecol. 2020. PMID: 32217114. doi:10.1016/j.ajog.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。